Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
LifeArc and the Gates Foundation launches groundbreaking new projects to lower the cost of monoclonal antibody production
-
We must confront this silent pandemic as a global collective
-
PACE announces £6 million funding for antibacterial treatment innovations to fill critical gap in R&D pipeline